{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:04:41Z","timestamp":1761156281962},"publisher-location":"Cham","reference-count":67,"publisher":"Springer International Publishing","isbn-type":[{"type":"print","value":"9783319596587"},{"type":"electronic","value":"9783319596594"}],"license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017]]},"DOI":"10.1007\/164_2017_23","type":"book-chapter","created":{"date-parts":[[2017,4,5]],"date-time":"2017-04-05T16:48:53Z","timestamp":1491410933000},"page":"329-353","source":"Crossref","is-referenced-by-count":8,"title":["Mesenchymal Stem Cell Therapy for the Treatment of Heart Failure Caused by Ischemic or Non-ischemic Cardiomyopathy: Immunosuppression and Its Implications"],"prefix":"10.1007","author":[{"given":"Michael J.","family":"Lipinski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dror","family":"Luger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen E.","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,4,6]]},"reference":[{"issue":"3","key":"23_CR1","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nbt.2816","volume":"32","author":"JA Ankrum","year":"2014","unstructured":"Ankrum JA, Ong JF, Karp JM (2014) Mesenchymal stem cells: immune evasive, not immune privileged. Nat Biotechnol 32(3):252\u2013260","journal-title":"Nat Biotechnol"},{"issue":"23","key":"23_CR2","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1016\/j.jacc.2013.02.071","volume":"61","author":"J Bartunek","year":"2013","unstructured":"Bartunek J, Behfar A, Dolatabadi D et al (2013) Cardiopoietic stem cell therapy in heart failure: the C-CURE (cardiopoietic stem cell therapy in heart failure) multicenter randomized trial with lineage-specified biologics. J Am Coll Cardiol 61(23):2329\u20132338","journal-title":"J Am Coll Cardiol"},{"key":"23_CR3","doi-asserted-by":"crossref","unstructured":"Bartunek J, Terzic A, Davison BA et al (2016) Cardiopoietic cell therapy for advanced ischemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial. Eur Heart J","DOI":"10.1093\/eurheartj\/ehw543"},{"issue":"20","key":"23_CR4","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1016\/j.jacc.2013.07.057","volume":"62","author":"T Ben-Mordechai","year":"2013","unstructured":"Ben-Mordechai T, Holbova R, Landa-Rouben N et al (2013) Macrophage subpopulations are essential for infarct repair with and without stem cell therapy. J Am Coll Cardiol 62(20):1890\u20131901","journal-title":"J Am Coll Cardiol"},{"issue":"9806","key":"23_CR5","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/S0140-6736(11)61590-0","volume":"378","author":"R Bolli","year":"2011","unstructured":"Bolli R, Chugh AR, D\u2019Amario D et al (2011) Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet 378(9806):1847\u20131857","journal-title":"Lancet"},{"issue":"2","key":"23_CR6","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10741-016-9533-z","volume":"21","author":"A Briasoulis","year":"2016","unstructured":"Briasoulis A, Androulakis E, Christophides T, Tousoulis D (2016) The role of inflammation and cell death in the pathogenesis, progression and treatment of heart failure. Heart Fail Rev 21(2):169\u2013176","journal-title":"Heart Fail Rev"},{"issue":"2","key":"23_CR7","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1161\/CIRCRESAHA.116.309717","volume":"120","author":"J Butler","year":"2017","unstructured":"Butler J, Epstein SE, Greene SJ et al (2017) Intravenous allogeneic mesenchymal stem cells for nonischemic cardiomyopathy: safety and efficacy results of a phase II-a randomized trial. Circ Res 120(2):332\u2013340","journal-title":"Circ Res"},{"issue":"5","key":"23_CR8","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1007\/s12015-015-9601-0","volume":"11","author":"A Can","year":"2015","unstructured":"Can A, Ulus AT, Cinar O et al (2015) Human umbilical cord mesenchymal stromal cell transplantation in myocardial ischemia (HUC-HEART trial). A study protocol of a phase 1\/2, controlled and randomized trial in combination with coronary artery bypass grafting. Stem Cell Rev 11(5):752\u2013760","journal-title":"Stem Cell Rev"},{"issue":"5","key":"23_CR9","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1002\/jcb.20886","volume":"98","author":"AI Caplan","year":"2006","unstructured":"Caplan AI, Dennis JE (2006) Mesenchymal stem cells as trophic mediators. J Cell Biochem 98(5):1076\u20131084","journal-title":"J Cell Biochem"},{"issue":"3","key":"23_CR10","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1160\/TH13-03-0211","volume":"110","author":"F Carbone","year":"2013","unstructured":"Carbone F, Nencioni A, Mach F, Vuilleumier N, Montecucco F (2013) Pathophysiological role of neutrophils in acute myocardial infarction. Thromb Haemost 110(3):501\u2013514","journal-title":"Thromb Haemost"},{"issue":"11","key":"23_CR11","first-page":"552","volume":"18","author":"S Chen","year":"2006","unstructured":"Chen S, Liu Z, Tian N et al (2006) Intracoronary transplantation of autologous bone marrow mesenchymal stem cells for ischemic cardiomyopathy due to isolated chronic occluded left anterior descending artery. J Invasive Cardiol 18(11):552\u2013556","journal-title":"J Invasive Cardiol"},{"issue":"7","key":"23_CR12","doi-asserted-by":"crossref","first-page":"814","DOI":"10.3109\/14653249.2011.574118","volume":"13","author":"SP Chin","year":"2011","unstructured":"Chin SP, Poey AC, Wong CY et al (2011) Intramyocardial and intracoronary autologous bone marrow-derived mesenchymal stromal cell treatment in chronic severe dilated cardiomyopathy. Cytotherapy 13(7):814\u2013821","journal-title":"Cytotherapy"},{"issue":"16","key":"23_CR13","doi-asserted-by":"crossref","first-page":"4779","DOI":"10.3748\/wjg.v21.i16.4779","volume":"21","author":"R Chinnadurai","year":"2015","unstructured":"Chinnadurai R, Ng S, Velu V, Galipeau J (2015) Challenges in animal modelling of mesenchymal stromal cell therapy for inflammatory bowel disease. World J Gastroenterol 21(16):4779\u20134787","journal-title":"World J Gastroenterol"},{"issue":"25","key":"23_CR14","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","volume":"107","author":"ES Chung","year":"2003","unstructured":"Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT (2003) Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation 107(25):3133\u20133140","journal-title":"Circulation"},{"issue":"2","key":"23_CR15","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jchf.2013.11.006","volume":"2","author":"S Deftereos","year":"2014","unstructured":"Deftereos S, Giannopoulos G, Panagopoulou V et al (2014) Anti-inflammatory treatment with colchicine in stable chronic heart failure: a prospective, randomized study. JACC Heart Fail 2(2):131\u2013137","journal-title":"JACC Heart Fail"},{"issue":"16","key":"23_CR16","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1161\/01.CIR.103.16.2055","volume":"103","author":"A Deswal","year":"2001","unstructured":"Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL (2001) Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 103(16):2055\u20132059","journal-title":"Circulation"},{"issue":"11","key":"23_CR17","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1161\/CIRCRESAHA.108.175943","volume":"102","author":"S Dimmeler","year":"2008","unstructured":"Dimmeler S, Leri A (2008) Aging and disease as modifiers of efficacy of cell therapy. Circ Res 102(11):1319\u20131330","journal-title":"Circ Res"},{"issue":"4","key":"23_CR18","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/14653240600855905","volume":"8","author":"M Dominici","year":"2006","unstructured":"Dominici M, Le Blanc K, Mueller I et al (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8(4):315\u2013317","journal-title":"Cytotherapy"},{"issue":"13","key":"23_CR19","doi-asserted-by":"crossref","first-page":"4057","DOI":"10.1182\/blood-2005-03-1004","volume":"106","author":"N Eliopoulos","year":"2005","unstructured":"Eliopoulos N, Stagg J, Lejeune L, Pommey S, Galipeau J (2005) Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice. Blood 106(13):4057\u20134065","journal-title":"Blood"},{"issue":"2","key":"23_CR20","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jcmg.2014.10.009","volume":"8","author":"H Emami","year":"2015","unstructured":"Emami H, Singh P, MacNabb M et al (2015) Splenic metabolic activity predicts risk of future cardiovascular events: demonstration of a cardiosplenic axis in humans. JACC Cardiovasc Imaging 8(2):121\u2013130","journal-title":"JACC Cardiovasc Imaging"},{"key":"23_CR21","volume":"12","author":"SA Fisher","year":"2016","unstructured":"Fisher SA, Doree C, Mathur A, Taggart DP, Martin-Rendon E (2016) Stem cell therapy for chronic ischaemic heart disease and congestive heart failure. Cochrane Database Syst Rev 12:CD007888","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"23_CR22","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1093\/eurheartj\/ehi818","volume":"27","author":"T Freyman","year":"2006","unstructured":"Freyman T, Polin G, Osman H et al (2006) A quantitative, randomized study evaluating three methods of mesenchymal stem cell delivery following myocardial infarction. Eur Heart J 27(9):1114\u20131122","journal-title":"Eur Heart J"},{"issue":"18","key":"23_CR23","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1001\/jama.296.18.2217","volume":"296","author":"M Gheorghiade","year":"2006","unstructured":"Gheorghiade M, Abraham WT, Albert NM et al (2006) Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 296(18):2217\u20132226","journal-title":"JAMA"},{"issue":"4","key":"23_CR24","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nm0405-367","volume":"11","author":"M Gnecchi","year":"2005","unstructured":"Gnecchi M, He H, Liang OD et al (2005) Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med 11(4):367\u2013368","journal-title":"Nat Med"},{"issue":"11","key":"23_CR25","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1161\/CIRCRESAHA.108.176826","volume":"103","author":"M Gnecchi","year":"2008","unstructured":"Gnecchi M, Zhang Z, Ni A, Dzau VJ (2008) Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res 103(11):1204\u20131219","journal-title":"Circ Res"},{"issue":"2","key":"23_CR26","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jacc.2014.10.040","volume":"65","author":"S Golpanian","year":"2015","unstructured":"Golpanian S, El-Khorazaty J, Mendizabal A et al (2015) Effect of aging on human mesenchymal stem cell therapy in ischemic cardiomyopathy patients. J Am Coll Cardiol 65(2):125\u2013132","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"23_CR27","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1161\/CIRCRESAHA.115.307347","volume":"118","author":"M Gyongyosi","year":"2016","unstructured":"Gyongyosi M, Wojakowski W, Navarese EP, Moye LA (2016) Meta-analyses of human cell-based cardiac regeneration therapies: controversies in meta-analyses results on cardiac cell-based regenerative studies. Circ Res 118(8):1254\u20131263","journal-title":"Circ Res"},{"issue":"22","key":"23_CR28","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1001\/jama.2012.25321","volume":"308","author":"JM Hare","year":"2012","unstructured":"Hare JM, Fishman JE, Gerstenblith G et al (2012) Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA 308(22):2369\u20132379","journal-title":"JAMA"},{"issue":"5","key":"23_CR29","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.jacc.2016.11.009","volume":"69","author":"JM Hare","year":"2017","unstructured":"Hare JM, DiFede DL, Rieger AC, Florea V, Landin AM, El-Khorazaty J, Khan A, Mushtaq M, Lowery MH, Byrnes JJ, Hendel RC, Cohen MG, Alfonso CE, Valasaki K, Pujol MV, Golpanian S, Ghersin E, Fishman JE, Pattany P, Gomes SA, Delgado C, Miki R, Abuzeid F, Vidro-Casiano M, Premer C, Medina A, Porras V, Hatzistergos KE, Anderson E, Mendizabal A, Mitrani R, Heldman AW (2017) Randomized comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic dilated cardiomyopathy: POSEIDON-DCM trial. J Am Coll Cardiol 69(5):526\u2013537. doi:\n10.1016\/j.jacc.2016.11.009","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"23_CR30","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1001\/jama.2013.282909","volume":"311","author":"AW Heldman","year":"2014","unstructured":"Heldman AW, DiFede DL, Fishman JE et al (2014) Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. JAMA 311(1):62\u201373","journal-title":"JAMA"},{"key":"23_CR31","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw002","author":"M Horckmans","year":"2016","unstructured":"Horckmans M, Ring L, Duchene J, Santovito D, Schloss MJ, Drechsler M, Weber C, Soehnlein O, Steffens S (2016) Neutrophils orchestrate post-myocardial infarction healing by polarizing macrophages towards a reparative phenotype. Eur Heart J. doi:\n10.1093\/eurheartj\/ehw002","journal-title":"Eur Heart J"},{"issue":"2","key":"23_CR32","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1161\/CIRCRESAHA.113.301720","volume":"114","author":"MA Ismahil","year":"2014","unstructured":"Ismahil MA, Hamid T, Bansal SS, Patel B, Kingery JR, Prabhu SD (2014) Remodeling of the mononuclear phagocyte network underlies chronic inflammation and disease progression in heart failure: critical importance of the cardiosplenic axis. Circ Res 114(2):266\u2013282","journal-title":"Circ Res"},{"issue":"18","key":"23_CR33","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1016\/j.jacc.2015.09.010","volume":"66","author":"AA Kelkar","year":"2015","unstructured":"Kelkar AA, Butler J, Schelbert EB et al (2015) Mechanisms Contributing to the Progression of ischemic and nonischemic dilated cardiomyopathy: possible modulating effects of paracrine activities of stem cells. J Am Coll Cardiol 66(18):2038\u20132047","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"23_CR34","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1161\/01.RES.0000137878.26174.66","volume":"95","author":"T Kinnaird","year":"2004","unstructured":"Kinnaird T, Stabile E, Burnett MS, Epstein SE (2004a) Bone-marrow-derived cells for enhancing collateral development: mechanisms, animal data, and initial clinical experiences. Circ Res 95(4):354\u2013363","journal-title":"Circ Res"},{"issue":"5","key":"23_CR35","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1161\/01.RES.0000118601.37875.AC","volume":"94","author":"T Kinnaird","year":"2004","unstructured":"Kinnaird T, Stabile E, Burnett MS et al (2004b) Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res 94(5):678\u2013685","journal-title":"Circ Res"},{"issue":"1","key":"23_CR36","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11373-004-8183-7","volume":"12","author":"E Klyushnenkova","year":"2005","unstructured":"Klyushnenkova E, Mosca JD, Zernetkina V et al (2005) T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. J Biomed Sci 12(1):47\u201357","journal-title":"J Biomed Sci"},{"key":"23_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/term.2394","author":"H Kubo","year":"2016","unstructured":"Kubo H, Takamura K, Nagaya N, Ohgushi H (2016) The effect of serum on the proliferation of bone marrow-derived mesenchymal stem cells from aged donors and donors with\/without chronic heart failure. J Tissue Eng Regen Med. doi:\n10.1002\/term.2394","journal-title":"J Tissue Eng Regen Med"},{"issue":"1","key":"23_CR38","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.pcl.2009.12.001","volume":"57","author":"AC Lankester","year":"2010","unstructured":"Lankester AC, Ball LM, Lang P, Handgretinger R (2010) Immunotherapy in the context of hematopoietic stem cell transplantation: the emerging role of natural killer cells and mesenchymal stromal cells. Pediatr Clin North Am 57(1):97\u2013121","journal-title":"Pediatr Clin North Am"},{"issue":"1","key":"23_CR39","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/CIRCRESAHA.116.304872","volume":"116","author":"SJ Lorkeers","year":"2015","unstructured":"Lorkeers SJ, Eding JE, Vesterinen HM et al (2015) Similar effect of autologous and allogeneic cell therapy for ischemic heart disease: systematic review and meta-analysis of large animal studies. Circ Res 116(1):80\u201386","journal-title":"Circ Res"},{"issue":"3","key":"23_CR40","first-page":"587","volume":"7","author":"W Lu","year":"2015","unstructured":"Lu W, Tang Y, Zhang Z et al (2015) Inhibiting the mobilization of Ly6C(high) monocytes after acute myocardial infarction enhances the efficiency of mesenchymal stromal cell transplantation and curbs myocardial remodeling. Am J Transl Res 7(3):587\u2013597","journal-title":"Am J Transl Res"},{"key":"23_CR41","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.117.310599","author":"D Luger","year":"2017","unstructured":"Luger D, Lipinski MJ, Westman PC, Glover DK, Dimastromatteo J, Frias JC, Albelda MT, Sikora S, Kharazi A, Vertelov G, Waksman R, Epstein SE (2017) Intravenously-delivered mesenchymal stem cells: systemic anti-inflammatory effects improve left ventricular dysfunction in acute myocardial infarction and ischemic cardiomyopathy. Circ Res. doi:\n10.1161\/CIRCRESAHA.117.310599","journal-title":"Circ Res"},{"issue":"9819","key":"23_CR42","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(12)60195-0","volume":"379","author":"RR Makkar","year":"2012","unstructured":"Makkar RR, Smith RR, Cheng K et al (2012) Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet 379(9819):895\u2013904","journal-title":"Lancet"},{"issue":"1","key":"23_CR43","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1161\/CIRCULATIONAHA.111.042598","volume":"125","author":"K Malliaras","year":"2012","unstructured":"Malliaras K, Li TS, Luthringer D et al (2012) Safety and efficacy of allogeneic cell therapy in infarcted rats transplanted with mismatched cardiosphere-derived cells. Circulation 125(1):100\u2013112","journal-title":"Circulation"},{"issue":"2","key":"23_CR44","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jacc.2013.08.724","volume":"63","author":"K Malliaras","year":"2014","unstructured":"Malliaras K, Makkar RR, Smith RR et al (2014) Intracoronary cardiosphere-derived cells after myocardial infarction: evidence of therapeutic regeneration in the final 1-year results of the CADUCEUS trial (Cardiosphere-derived autologous stem cells to reverse ventricular dysfunction). J Am Coll Cardiol 63(2):110\u2013122","journal-title":"J Am Coll Cardiol"},{"issue":"27","key":"23_CR45","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1093\/eurheartj\/ehv136","volume":"36","author":"AB Mathiasen","year":"2015","unstructured":"Mathiasen AB, Qayyum AA, Jorgensen E et al (2015) Bone marrow-derived mesenchymal stromal cell treatment in patients with severe ischaemic heart failure: a randomized placebo-controlled trial (MSC-HF trial). Eur Heart J 36(27):1744\u20131753","journal-title":"Eur Heart J"},{"issue":"9252","key":"23_CR46","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0140-6736(00)03617-5","volume":"357","author":"P Menasche","year":"2001","unstructured":"Menasche P, Hagege AA, Scorsin M et al (2001) Myoblast transplantation for heart failure. Lancet 357(9252):279\u2013280","journal-title":"Lancet"},{"issue":"4","key":"23_CR47","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1161\/CIR.0000000000000152","volume":"131","author":"D Mozaffarian","year":"2015","unstructured":"Mozaffarian D, Benjamin EJ, Go AS et al (2015) Heart disease and stroke statistics\u20132015 update: a report from the American Heart Association. Circulation 131(4):e29\u2013322","journal-title":"Circulation"},{"issue":"15","key":"23_CR48","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/j.jacc.2015.02.034","volume":"65","author":"M Nahrendorf","year":"2015","unstructured":"Nahrendorf M, Frantz S, Swirski FK et al (2015) Imaging systemic inflammatory networks in ischemic heart disease. J Am Coll Cardiol 65(15):1583\u20131591","journal-title":"J Am Coll Cardiol"},{"key":"23_CR49","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.clim.2016.11.010","volume":"175","author":"S Ong","year":"2016","unstructured":"Ong S, Rose NR, Cihakova D (2016) Natural killer cells in inflammatory heart disease. Clin Immunol 175:26\u201333","journal-title":"Clin Immunol"},{"issue":"3","key":"23_CR50","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1365-2796.2012.02517.x","volume":"272","author":"S Orn","year":"2012","unstructured":"Orn S, Ueland T, Manhenke C et al (2012) Increased interleukin-1beta levels are associated with left ventricular hypertrophy and remodelling following acute ST segment elevation myocardial infarction treated by primary percutaneous coronary intervention. J Intern Med 272(3):267\u2013276","journal-title":"J Intern Med"},{"issue":"5","key":"23_CR51","doi-asserted-by":"crossref","first-page":"929","DOI":"10.3727\/096368915X689758","volume":"25","author":"Y Peng","year":"2016","unstructured":"Peng Y, Pan W, Ou Y et al (2016) Extracardiac-Lodged mesenchymal stromal cells propel an inflammatory response against myocardial infarction via paracrine effects. Cell Transplant 25(5):929\u2013935","journal-title":"Cell Transplant"},{"issue":"6","key":"23_CR52","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1161\/CIRCRESAHA.115.306332","volume":"117","author":"EC Perin","year":"2015","unstructured":"Perin EC, Borow KM, Silva GV et al (2015) A phase II dose-escalation study of allogeneic mesenchymal precursor cells in patients with ischemic or nonischemic heart failure. Circ Res 117(6):576\u2013584","journal-title":"Circ Res"},{"issue":"11","key":"23_CR53","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1634\/stemcells.2007-0637","volume":"25","author":"DG Phinney","year":"2007","unstructured":"Phinney DG, Prockop DJ (2007) Concise review: mesenchymal stem\/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair \u2013 current views. Stem Cells 25(11):2896\u20132902","journal-title":"Stem Cells"},{"issue":"6","key":"23_CR54","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/01.tp.0000258649.23081.a3","volume":"83","author":"AJ Poncelet","year":"2007","unstructured":"Poncelet AJ, Vercruysse J, Saliez A, Gianello P (2007) Although pig allogeneic mesenchymal stem cells are not immunogenic in vitro, intracardiac injection elicits an immune response in vivo. Transplantation 83(6):783\u2013790","journal-title":"Transplantation"},{"issue":"6","key":"23_CR55","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1161\/CIRCRESAHA.113.300219","volume":"113","author":"SK Sanganalmath","year":"2013","unstructured":"Sanganalmath SK, Bolli R (2013) Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions. Circ Res 113(6):810\u2013834","journal-title":"Circ Res"},{"issue":"1","key":"23_CR56","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1634\/stemcells.2004-0359","volume":"24","author":"PA Sotiropoulou","year":"2006","unstructured":"Sotiropoulou PA, Perez SA, Gritzapis AD, Baxevanis CN, Papamichail M (2006) Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 24(1):74\u201385","journal-title":"Stem Cells"},{"issue":"3","key":"23_CR57","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1182\/blood-2007-02-074997","volume":"111","author":"GM Spaggiari","year":"2008","unstructured":"Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari MC, Moretta L (2008) Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood 111(3):1327\u20131333","journal-title":"Blood"},{"issue":"6116","key":"23_CR58","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1126\/science.1230719","volume":"339","author":"FK Swirski","year":"2013","unstructured":"Swirski FK, Nahrendorf M (2013) Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure. Science 339(6116):161\u2013166","journal-title":"Science"},{"issue":"2","key":"23_CR59","doi-asserted-by":"crossref","first-page":"H886","DOI":"10.1152\/ajpheart.00142.2006","volume":"291","author":"M Takahashi","year":"2006","unstructured":"Takahashi M, Li TS, Suzuki R et al (2006) Cytokines produced by bone marrow cells can contribute to functional improvement of the infarcted heart by protecting cardiomyocytes from ischemic injury. Am J Physiol Heart Circ Physiol 291(2):H886\u2013H893","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"2","key":"23_CR60","doi-asserted-by":"crossref","first-page":"196","DOI":"10.7150\/thno.7976","volume":"5","author":"B Tao","year":"2015","unstructured":"Tao B, Cui M, Wang C et al (2015) Percutaneous intramyocardial delivery of mesenchymal stem cells induces superior improvement in regional left ventricular function compared with bone marrow mononuclear cells in porcine myocardial infarcted heart. Theranostics 5(2):196\u2013205","journal-title":"Theranostics"},{"issue":"5","key":"23_CR61","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000338","volume":"2","author":"KS Telukuntla","year":"2013","unstructured":"Telukuntla KS, Suncion VY, Schulman IH, Hare JM (2013) The advancing field of cell-based therapy: insights and lessons from clinical trials. J Am Heart Assoc 2(5):e000338","journal-title":"J Am Heart Assoc"},{"issue":"7","key":"23_CR62","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s12265-015-9643-3","volume":"8","author":"TI Spoel van der","year":"2015","unstructured":"van der Spoel TI, Gathier WA, Koudstaal S et al (2015) Autologous mesenchymal stem cells show more benefit on systolic function compared to bone marrow mononuclear cells in a porcine model of chronic myocardial infarction. J Cardiovasc Transl Res 8(7):393\u2013403","journal-title":"J Cardiovasc Transl Res"},{"issue":"11 Suppl 1","key":"23_CR63","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1161\/CIRCULATIONAHA.112.000230","volume":"128","author":"B Vrtovec","year":"2013","unstructured":"Vrtovec B, Poglajen G, Lezaic L et al (2013) Comparison of transendocardial and intracoronary CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation 128(11 Suppl 1):S42\u2013S49","journal-title":"Circulation"},{"issue":"11","key":"23_CR64","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1161\/01.RES.0000193596.94936.2c","volume":"97","author":"DH Walter","year":"2005","unstructured":"Walter DH, Haendeler J, Reinhold J et al (2005) Impaired CXCR4 signaling contributes to the reduced neovascularization capacity of endothelial progenitor cells from patients with coronary artery disease. Circ Res 97(11):1142\u20131151","journal-title":"Circ Res"},{"issue":"17","key":"23_CR65","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1016\/j.jacc.2016.01.073","volume":"67","author":"PC Westman","year":"2016","unstructured":"Westman PC, Lipinski MJ, Luger D et al (2016) Inflammation as a driver of adverse left ventricular remodeling after acute myocardial infarction. J Am Coll Cardiol 67(17):2050\u20132060","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"23_CR66","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/eurjhf\/hfr122","volume":"13","author":"BJ Wrigley","year":"2011","unstructured":"Wrigley BJ, Lip GY, Shantsila E (2011) The role of monocytes and inflammation in the pathophysiology of heart failure. Eur J Heart Fail 13(11):1161\u20131171","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"23_CR67","volume":"9","author":"K Yee","year":"2014","unstructured":"Yee K, Malliaras K, Kanazawa H et al (2014) Allogeneic cardiospheres delivered via percutaneous transendocardial injection increase viable myocardium, decrease scar size, and attenuate cardiac dilatation in porcine ischemic cardiomyopathy. PLoS One 9(12):e113805","journal-title":"PLoS One"}],"container-title":["Handbook of Experimental Pharmacology","Heart Failure"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/164_2017_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,9]],"date-time":"2017-06-09T12:27:18Z","timestamp":1497011238000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/164_2017_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"ISBN":["9783319596587","9783319596594"],"references-count":67,"URL":"https:\/\/doi.org\/10.1007\/164_2017_23","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"type":"print","value":"0171-2004"},{"type":"electronic","value":"1865-0325"}],"subject":[],"published":{"date-parts":[[2017]]}}}